Amgen has reported positive results from its Phase 2 trial of MariTide, a new obesity drug that has shown potential in helping participants lose up to 20% of their body weight over a year.
The trial enrolled 465 participants with obesity or overweight conditions, and the results showed that participants without diabetes experienced weight loss of up to 20%, while those with diabetes lost up to 17%. The drug also demonstrated efficacy in lowering blood sugar levels among diabetic participants.
However, analysts have expressed concerns about a higher dropout rate among trial participants using MariTide compared to those on weekly medications from Eli Lilly and Novo Nordisk. Approximately 11% of individuals in the dose escalation arms discontinued treatment due to side effects, which is higher than the dropout rate reported in Phase 3 trials for Zepbound.
The obesity drug market has seen significant investment, driven by the success of existing treatments like Wegovy and Zepbound. Analysts predict that the market for obesity and diabetes drugs targeting GLP-1 could exceed $100 billion in annual sales. Amgen faces challenges in this competitive landscape, as Novo Nordisk and Eli Lilly are advancing successor obesity drugs through Phase 3 development. These potential new entrants could reach the market before MariTide, further complicating Amgen's efforts to establish a share of the obesity treatment market.
MariTide's main differentiating factor may be its less frequent monthly dosing compared to its competitors. Analysts have provided mixed reviews regarding MariTide's trial results, with some feeling disappointed and others suggesting that it could match Zepbound's weight loss results more quickly.
As Amgen prepares for Phase 3 trials, the company plans to explore MariTide's efficacy in treating not only obesity but also related conditions such as heart disease, sleep apnea, and kidney disorders. This broader focus may enhance MariTide's appeal and marketability if it can demonstrate additional health benefits beyond weight loss.
The success of MariTide could significantly impact Amgen's financial outlook and position within the pharmaceutical industry, as the demand for effective obesity treatments continues to grow.